Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Fixed Sequence, Open-label, Drug-drug Interaction Study to Evaluate the Effect of GLPG3970 on the Pharmacokinetics of Sulfasalazine in Adult, Healthy Subjects

Next Previous
X
Search
Trial Profile

A Phase 1, Fixed Sequence, Open-label, Drug-drug Interaction Study to Evaluate the Effect of GLPG3970 on the Pharmacokinetics of Sulfasalazine in Adult, Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GLPG 3970 (Primary) ; Sulfasalazine (Primary)
  • Indications Inflammatory bowel diseases; Psoriasis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus; Ulcerative colitis
  • Focus Pharmacokinetics
  • Sponsors Galapagos NV

    • Most Recent Events

    • 24 Mar 2023 Results assessing the pharmacokinetics of Glpg3970 on sulfasalazine and methotrexate and safety in healthy adults from NCT04720183 and EudraCT2020-000391-37 studies, presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 09 Jul 2021 Status changed from recruiting to completed.
    • 14 Apr 2021 Planned End Date changed from 1 Apr 2021 to 1 Jul 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top